FVD - First Trust Value Line Dividend ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
30.08
-0.03 (-0.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close30.11
Open30.16
Bid0.00 x 900
Ask0.00 x 4000
Day's Range30.07 - 30.26
52 Week Range28.82 - 31.85
Volume499,283
Avg. Volume479,354
Net Assets4.04B
NAV29.87
PE Ratio (TTM)N/A
Yield2.13%
YTD Return-2.80%
Beta (3y)0.70
Expense Ratio (net)0.70%
Inception Date2003-08-19
Trade prices are not sourced from all markets
  • Novartis Gains Ground, Completes the AveXis Acquisition
    Market Realist5 days ago

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.

  • GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend
    Market Realist25 days ago

    GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend

    GlaxoSmithKline (GSK) reported revenues of ~7.2 billion pounds for 1Q18 on April 25, a ~2% decline from its ~7.3 billion pounds in 1Q17. This change includes 4% growth in revenues at constant exchange rates, offset by a 6% decrease in revenues due to the negative impact of foreign exchange. The company’s stock is listed on the London Stock Exchange, and the company reports its financial statements in pounds sterling. GlaxoSmithKline reported revenues of ~7.2 billion in 1Q18, a ~2% decline from its revenues of ~7.3 billion pounds in 1Q17. ...

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realist27 days ago

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realist27 days ago

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
    Market Realist29 days ago

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.

  • Expectations from Novartis’s 1Q18 Earnings
    Market Realistlast month

    Expectations from Novartis’s 1Q18 Earnings

    Headquartered in Basel, Switzerland, Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.

  • Novartis’s Stock Performance following the AveXis Agreement
    Market Realistlast month

    Novartis’s Stock Performance following the AveXis Agreement

    Novartis AG (NVS) announced an agreement and plan for a merger with AveXis on April 9, 2018. Following the recovery of major US indexes after the US-China trade war concerns—and also due to the announcement of the acquisition—Novartis AG’s ADR (American depositary receipt) reported a 1.1% rise in its price to close at $81.07 on April 9 compared to its previous close of $80.20 on April 6.

  • How Merck Stock Has Performed Recently
    Market Realist2 months ago

    How Merck Stock Has Performed Recently

    What Analysts Recommend for Merck in March 2018A look at Merck

  • How Novartis’s Revenues Trended in 4Q17
    Market Realist2 months ago

    How Novartis’s Revenues Trended in 4Q17

    How Novartis Fared in 4Q17

  • Analyst Recommendations for Johnson & Johnson in February 2018
    Market Realist2 months ago

    Analyst Recommendations for Johnson & Johnson in February 2018

    As we’ve already seen, Johnson & Johnson reported revenues of ~$20.2 billion in 4Q17, an 11.5% growth in revenues compared to ~$18.1 billion in 4Q16. Analysts also estimate that Johnson & Johnson could generate EPS (earnings per share) of $2.01 on revenues of ~$19.4 billion in 1Q18, a 9.2% growth compared to 1Q17. Analyst recommendations show a 12-month target price of $150.62 per share compared to its last price of $132.02 per share on February 23, 2018.

  • These Factors Could Drive SO’s Dividend Growth
    Market Realist3 months ago

    These Factors Could Drive SO’s Dividend Growth

    The Top S&P 500 Utility Dividend Growers: Part 2

  • Sanofi’s Quarterly Revenue Trend in 4Q17
    Market Realist3 months ago

    Sanofi’s Quarterly Revenue Trend in 4Q17

    Must-Read Notes on Sanofi's 4Q17 EarningsSanofi’s 4Q17 revenues

  • First Trust Launches New Blockchain ETF To Meet Demand
    Investor's Business Daily3 months ago

    First Trust Launches New Blockchain ETF To Meet Demand

    First Trust has come a long way since its foray into the exchange traded fund universe more than a decade ago.

  • A Look at Ablynx and Sanofi’s Existing Partnership
    Market Realist3 months ago

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros. Ablynx and Sanofi had a successful existing partnership for multiple sclerosis research and immunoinflammatory diseases. Under the agreement terms, Sanofi gained access Ablynx’s scientists, certain nanobodies in its product portfolio, and Ablynx’s proprietary nanobody platform.

  • Novartis’s 4Q17 Revenues and Fiscal 2017 Revenues
    Market Realist4 months ago

    Novartis’s 4Q17 Revenues and Fiscal 2017 Revenues

    Must-Read Notes on Novartis’s 4Q17 and 2017 EarningsAn overview of Novartis

  • GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916
    Market Realist4 months ago

    GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916

    GlaxoSmithKline (GSK) estimates the global incidence of MM to be close to 124,000 with 30,000 patients in the US, 27,000 in EU5, and around 8,000 in Japan. The above diagram shows that despite the advent of multiple new treatment options from companies like Celgene (CELG), Johnson & Johnson (JNJ), and Amgen (AMGN), the five-year survival rate for MM patients continues to be below 50%. In 2016, the global market value of MM was around $12 billion, a year-over-year (or YoY) rise of 40%.

  • Sanofi to Acquire Bioverativ
    Market Realist4 months ago

    Sanofi to Acquire Bioverativ

    Sanofi to Acquire Bioverativ and AblynxAcquisition deal

  • Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline
    Market Realist4 months ago

    Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline

    A Look at GlaxoSmithKline's Growth Drivers in 2018FDA approval of Trelegy Ellipta

  • How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?
    Market Realist4 months ago

    How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?

    How Novartis Is Positioned for 2018

  • Why Assurant Has a Positive Outlook despite a Weak 2017
    Market Realist4 months ago

    Why Assurant Has a Positive Outlook despite a Weak 2017

    Last Year's Top 18 S&P 500 Stocks by Dividend Growth: Part 2

  • Market Realist6 months ago

    Behind Novartis’s Respiratory Drug Performance in 3Q17

    In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.

  • Benzinga7 months ago

    An ETF For Dividend Achievers

    Income investors looking for stocks that have achieved dividend achievers status do not need to confine their search to large-cap equities. A new exchange traded fund from First Trust provides a basket ...

  • Market Realist7 months ago

    How Do Aerospace and Defense Sector Dividends Look?

    This series will discuss the top ten aerospace and defense products and services companies based on their dividend yields.

  • Business Wire8 months ago

    First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds

    First Trust Advisors L.P. announces the declaration of distributions for 116 exchange-traded funds advised by FTA.

  • Market Realist8 months ago

    How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

    In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.